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Abstract
Background: Parkinson’s disease patients are at an elevated risk of developing cognitive impairment. Although
cognitive impairment is one of the strongest predictors of quality of life, dopaminergic anti-parkinsonian medications
are designed to target motor symptoms. However, there is substantial evidence that dopamine also impacts cognition,
in particular working memory. It is therefore critical for movement disorders physicians to understand the potential
dopaminergic effects on working memory when prescribing these medications.
Verbal digit span tasks offer a potentially straightforward and quick assessment of baseline working memory. Moreover,
Digit Span Backward was recently validated as a screening tool for mild cognitive impairment in Parkinson’s disease
when participants were medicated. Research indicates that the interaction between dopamine and working memory
follows an Inverted-U shaped curve, but the effect of dopamine on Digit Span has not been well studied.
Our study seeks to: (1) determine the validity of verbal Digit Spans for detecting cognitive impairment in Parkinson’s
disease patients both ON and OFF medications; and (2) ascertain the effects of dopaminergic medications on verbal
Digit Span.
Methods: We recruited 64 Parkinson’s disease patients and 22 age-and education-matched controls. Parkinson’s patients
completed Digit Span Backward and Digit Span Forward ON and OFF medications, while healthy controls completed
them once. All participants were categorized by cognitive diagnosis using level-II consensus criteria.
Results: Digit Span Backward successfully identified mild cognitive impairment in Parkinson’s disease, both ON
and OFF medications. Combining patients with and without cognitive impairment, we found that dopamine
significantly improved performance on Digit Span Backward, but not Forward. In a secondary analysis, we found
this dopaminergic improvement was restricted to the Low baseline working memory group; the High baseline
working memory group was unaffected.
Conclusions: This study provides evidence for Digit Span Backward as a screening tool for working memory impairment
in Parkinson’s disease and for its utility in measuring baseline working memory. Moreover, it reveals a partial beneficial
effect of dopamine on Digit Span in Parkinson’s disease patients.
Keywords: Parkinson’s disease, PD, Digit span backward, Digit span forward, Dopamine, Working memory, Cognitive
impairment, Dementia
Background
Parkinson’s disease (PD) patients are at an elevated risk
of developing cognitive impairment and dementia [1, 2].
One common, early impairment is a working memory
(WM) deficit [3]. WM is the ability to hold and manipu-
late information in short-term storage for task-relevant
purposes; WM is crucial to many higher level cognitive
processes such as learning, language comprehension,
and reasoning [4, 5]. Although cognitive impairment is
one of the strongest predictors of quality of life [6, 7],
there are limited treatments targeting PD cognitive
symptoms [8]. In the clinic, motor symptoms are
treated with dopaminergic medications that alleviate
the chronic dopamine depletion that defines PD; how-
ever, the effects of these medications on cognition are
still poorly understood.
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In 1979, Brozoski et al first demonstrated that dopamine
depletion from the striatum to the prefrontal cortex in
monkeys led to severe impairment on a delayed response
task [9]. In the intervening years, there has been growing
evidence that dopamine and WM are closely linked
[10–17]. Today, research indicates that WM impair-
ment in PD is likely a down-stream effect of nigrostraital
dopamine depletion [18]. However, it remains unclear if
dopamine depletion is universally detrimental to WM and
whether dopamine replacement leads to improvement for
all individuals. In a recent review, Cools and D’Esposito
argued that poor WM reflects an imbalance between the
striatum and the prefrontal cortex, both of which are
modulated by dopamine [10, 16, 17, 19–23]. They pro-
posed a double Inverted-U model to describe the relation-
ship between dopamine and WM. This model predicts
that dopamine’s effect on WM depends on both individual
baseline WM and the specific task being tested [24]. The
model holds strong implications for the effects of dopa-
minergic medications on cognition in PD patients in par-
ticular; individuals with intrinsic deficits might benefit
from dopamine replacement while those with more super-
ior baseline WM capabilities might suffer. For this reason,
it is crucial for clinicians to be able to accurately deter-
mine baseline levels of WM in PD patients and predict
the effects of dopaminergic medications on WM.
Verbal digit span tasks offer a potentially straightfor-
ward and quick assessment of baseline WM. Biundo et
al recently validated Digit Span Backward as a diagnostic
tool for determining cognitive impairment in PD [25].
However, this study did not consider the possible effects
of dopamine since all individuals were tested ON dopa-
minergic medications. Owing to the strong evidence for
a dopaminergic effect on WM, it is pertinent to investigate
whether Digit Span remains a valid diagnostic tool OFF
medications. Moreover, previous studies that examined
the effect of dopamine and PD on Digit Span Backward
and Digit Span Forward have reported conflicting findings
[11, 26]. It is important to examine the effect of dopamin-
ergic medications on both tasks in a large PD sample.
Our study seeks to: (1) determine the validity of verbal
Digit Spans for detecting cognitive impairment in PD
patients; and (2) ascertain the effects of dopaminergic
medications on verbal Digit Span. In a secondary ana-
lysis, we explored the possibility of an Inverted-U effect
of dopamine on verbal Digit Span. We tested 64 PD




We recruited 64 participants with idiopathic Parkinson’s
disease from the Stanford Movement Disorders Clinic and
the surrounding community (Table 1). Inclusion criteria
were as follows: (1) Age between 45–90 years, (2) flu-
ency in English, (3) right-handed, (4) diagnosis of PD
by a board-certified neurologist with specialty training
in movement disorders (KLP) based on UK Parkinson’s
Disease Society Brain Bank criteria [27], (5) at least two
years of a PD diagnosis, (6) at least 20 % improvement
in the Movement Disorders Society-United Parkinson’s
disease Rating Scale motor score (MDS-UPDRS-III)
[28] when ON dopaminergic medications, and (7) no
history of other significant neurological disease, serious
psychiatric illness, substance abuse, or head trauma.
In addition, we recruited 22 age- and education-matched
healthy controls (HC). Inclusion criteria were as follows:
(1) Age between 45–90 years, (2) fluency in English, (3)
right handed, (4) no history of significant neurological dis-
ease, serious psychiatric illness, substance abuse, or head
trauma and (5) no history of cognitive impairment during
phone screening.
All participants provided written informed consent to
participate in the study following protocols approved by
the Stanford Institutional Review Board.
Clinical evaluation
All PD and HC participants performed a neuropsycho-
logical battery that included at least two tests for each
of the five cognitive domains (memory, language, ex-
ecutive function, visuospatial, working memory/atten-
tion), a Montreal Cognitive Assessment (MoCA), and
the Clinical Dementia Rating (See Table 2). PD partici-
pants were categorized as PD without cognitive impair-
ment (PD no-MCI), PD with mild cognitive impairment
(PD-MCI), or PD with dementia (PDD) according to pub-
lished criteria [27, 29]. PD-MCI was defined as exceeding
1.5 standard deviations below age- and education-matched
normative values on two tests, either in the same domain
or separate ones [27]. A designation of dementia was re-
served for those individuals who received a score of greater
than or equal to 1 on the CDR [29]; all dementia patients
were independently categorized as impaired on multiple
domains [30]. As recommended by current criteria [27],
the comprehensive neuropsychological testing was per-
formed ON medications to minimize motoric interference
in testing.
In order to determine the effect of dopamine on
Verbal Digit Span, PD participants performed the
WAIS-IV Digit Span Backward and Digit Span Forward
twice, once in the OFF and once in the ON state, coun-
terbalanced, and with a least a two week interval period.
The Digit Span OFF and ON was performed on the
same day as the MDS-UPDRS-III OFF and ON, respect-
ively, to control for potential motor fluctuations. The
Neuropsychological battery was performed in the ON
medication state, as recommended, and on a separate
day [31]. Critically, we administered the oral version of
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the Digit Span to minimize potential bias from bradyki-
nesia or dyskinesias.
In PD participants, the OFF state was defined as ≥ 72 h
off extended release dopamine agonists, selective MAO-
B inhibitor, and long-acting levodopa, and ≥ 12 h off
short acting dopamine agonists and levodopa. The ON
state was defined as the patients taking their normal
daily medications in the optimally medicated state, as
determined by both the patient and the movement disor-
ders neurologist. We took steps to minimize the influ-
ence of motor fluctuations on the tests performed ON
medications. First, the researchers documented the
patient’s last dose of medications, and the next sched-
uled dose, to confirm the testing was during the optimal
time in relation to scheduled medications. Second, it
was documented that the patient remained in the ON
state throughout the 30 min of the MDS-UPDRS-III
and Digit Span. With regards to dopamine replacement
therapy, 41 participants were taking levodopa and a
dopamine agonist, 2 were taking levodopa and a MAO-
B inhibitor, 18 were taking levodopa, a dopamine agon-
ist, and a MAO-B inhibitor, 1 was taking a dopamine
agonist and a MAO-B inhibitor, 1 was taking only an
MAO-B inhibitor, and 1 was taking a combination of
Table 1 Demographics for healthy control and Parkinson’s disease participants
HC PD ALL PD no-MCI PD-MCI PDD p
N 22 64 28 22 14
Male/Female 8/14 35/29 13/15 14/8 8/6
Age (years)^ 65.10 ± 6.89 68.36 ± 7.91 65.11 ± 7.21 69.14 ± 7.98 73.21 ± 6.68 * #
Education (years)^ 16.81 ± 2.03 16.44 ± 2.42 16.48 ± 2.36 16.41 ± 2.56 16.71 ± 2.16 NS
Duration (years)^ n/a 5.92 ± 4.18 5.04 ± 3.47 6.64 ± 4.82 6.57 ± 4.38 NS
MDS-UPDRS III (OFF)^ n/a 37.47 ± 10.94 35.79 ± 10.53 34.00 ± 9.40 46.79 ± 9.37 # %
MDS-UPDRS III (ON)^ n/a 21.54 ± 11.11 19.81 ± 9.62 18.89 ± 10.32 29.85 ± 11.67 # %
LEDD^ n/a 695.4 ± 366.1 657.8 ± 382.7 831.8 ± 325.8 556.2 ± 344.1 NS
BDI^ 3.64 ± 3.88 11.13 ± 8.34 9.26 ± 7.58 11.09 ± 7.08 13.92 ± 11.39 **
BAI^ 2.68 ± 2.85 11.09 ± 8.80 11.43 ± 9.00 11.32 ± 8.34 10.04 ± 9.63 **
PD Parkinson’s disease, PDD PD with Dementia, PD-MCI PD with mild cognitive impairment, PD no-MCI PD with no cognitive impairment, HC healthy controls,
MDS-UPDRS III Movement Disorders Society-Unified Parkinson’s disease Rating Scale, motor scale, LEDD levodopa equivalent daily dose, BDI Beck’s Depression
Inventory, BAI Beck’s Anxiety Inventory
^ = mean ± standard deviation; * = p < .05 PDD vs HC; # = p < .05 PDD vs PD no-MCI; % = p < .05 PDD vs PD-MCI; ** = p < 0.05 HC vs All PD groups;
NS = not significant
Table 2 Neuropsychological battery
HC PD no-MCI PD MCI PDD p-valueHC vs PD no-MCI
MoCA 27.52 ± 1.97 27.57 ± 2.01 23.50 ± 2.72 16.79 ± 1.97 0.93
DRS 140.19 ± 2.99 139.43 ± 2.81 135.45 ± 5.60 118.43 ± 16.01 0.37
CVLT LD Free 12.19 ± 2.71 11.07 ± 3.1 5.82 ± 2.75 3.29 ± 3.87 0.19
BVMT-R 10.1 ± 2.45 10.25 ± 1.92 5.64 ± 2.66 1.92 ± 2.47 0.80
JLO 26.24 ± 3.79 25.04 ± 3.39 21.14 ± 5.16 17.73 ± 5.85 0.25
HVOT 26.71 ± 1.91 25.88 ± 2.38 22.14 ± 4.28 17.69 ± 6.72 0.19
SDMT Oral 57.14 ± 9.46 56.46 ± 13.09 40.32 ± 11.98 17.75 ± 9.02 0.84
COWAT 46.43 ± 12.29 49 ± 12.96 33.77 ± 18.14 22.43 ± 10.06 0.49
WAIS-IV Digit total 17.43 ± 3.34 18.93 ± 3.89 15.82 ± 4.86 11.43 ± 2.24 0.16
Trails B 67.62 ± 23.44 68.39 ± 26.12 161.41 ± 91.46 280.5 ± 48.82 0.92
Stroop -2.16 ± 14.76 -3.29 ± 7.57 -7.55 ± 9.55 -12.07 ± 5.63 0.73
BNT 29.14 ± 0.91 27.82 ± 3.94 24.64 ± 4.96 25.43 ± 2.93 0.14
DKEFs Verbal 20.9 ±5. 12 22.32 ± 6.34 17.09 ± 6.22 10 ± 5.39 0.41
Table depicts the mean ± standard deviation for the demographic information and neuropsychological test data, with p-values derived from independent-sample
t-test between HC and PD no-MCI
PD Parkinson’s disease, HC Healthy control, MoCA Montreal Cognitive Assessment, CVLT LD Free California Verbal Learning Test, Long Delay Free Recall, BVMT-R
The Brief Visuospatial Memory Test-Revised, JLO Judgment of Line Orientation, HVOT Hooper Visual Organization Test, SDMT Oral Symbol Digit Modalities Test,
oral, COWAT Controlled Oral Word Association Test, WAIS-IV Digit total Wechsler Adult Intelligence Scale, Digit combined total, Trails B Trail Making Test B, Stroop
Golden version of Stroop test, Interference score, BNT Boston Naming Test, DKEFs Verbal Delis-Kaplan Executive Function System, Verbal score
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levodopa, a dopamine agonist, a MAO-B inhibitor and
a COMT inhibitor.
Statistical analysis
All statistical analysis were conducting using IBM SPSS
Statistics version 22.0 [32].
Results
Demographics
HC participants were age-matched with the overall PD
group and with the PD no-MCI and PD-MCI groups.)
HC and PD no-MCI groups were significantly younger
than the PDD group. There were no significant differ-
ences in education, duration of disease, levodopa equiva-
lent doses (LEDD), depression, or anxiety across all PD
groups (Table 1). In addition, there were no significant dif-
ferences between the HC and PD no-MCI groups on any
of the neuropsychological tests administered (Table 2). 59
participants completed the digit span ON and OFF dopa-
minergic medications, 1 completed it only OFF medica-
tions, and 4 completed it only ON medications. Only
participants with both an ON and an OFF session were
included in the analysis of medication effects. 34 par-
ticipants were tested ON medications first while 25
were tested OFF medications first. Repeat measure
ANOVAs with repeated factor Medications (ON, OFF)
and between-subjects factors Session (ON first, OFF
first) and Baseline WM (High, Low) did not reveal any
session effects.
Between group analysis
Due to the non-normal distribution of the PDD group,
Kruskal-Wallis tests with between-subjects factor Group
(HC, PD no-MCI, PD-MCI, PDD) and post-hoc stepwise
step-down procedures were used to analyze the differ-
ences in Digit Span Forward and Backward scores
between clinical groups (Fig. 1). Four separate Kruskal-
Wallis tests were conducted: Digit Span Forward with
PD OFF, Digit Span Forward with PD ON, Digit Span
Backward with PD OFF, and Digit Span Backward with
PD ON. Moreover, we conducted a Kruskal-Wallis test
with between-subject factor Group (HC, PD no-MCI,
PD-MCI, PDD) for the abbreviated digit span on the
MoCA.
Digit span forward, PD OFF
The effect of Group was significant (p < .005). Post-hoc
analysis revealed that PDD performed significantly worse
than PD no-MCI (p < .05). No other groups were signifi-
cantly different (Fig. 1a).
Digit span forward, PD ON
The effect of Group was significant (p < .001). Post-hoc
analysis revealed that PDD performed significantly worse
than PD no-MCI, PD-MCI, and HC (p < .05 in all cases).
No other groups were significantly different (Fig. 1c).
Digit span backward, PD OFF
The effect of Group was significant (p < .001). Post-hoc
analysis revealed that PDD performed significantly worse
than HC, PD no-MCI, and PD-MCI (p < .05 in all cases).
Moreover, the PD-MCI group performed significantly
worse than PD no-MCI and HC (both p < .05). PD no-
MCI was not significantly different from HC (Fig. 1b).
Digit span backward, PD ON
The effect of Group was significant (p < .001). Post-hoc
analysis revealed that PDD performed significantly worse
than HC, PD no-MCI, and PD-MCI (p < .05 in all cases).
PD-MCI also performed significantly worse than PD no-
MCI (p < .05). PD no-MCI and PD-MCI were not signifi-
cantly different from HC (Fig. 1d).
MoCA digit span sub-score
The effect of Group was not significant. The majority of
individuals, from all groups, achieved a perfect score of
2/2: 78.6 % of PDD, 90.9 % of PD-MCI, 89.3 % of PD
no-MCI and 100 % of HC.
Effect of dopaminergic medication
In order to isolate the effect of dopaminergic medica-
tions on WM, as measured by Digit Spans, we compared
performance within groups ON and OFF medications.
For PD-MCI and PD no-MCI groups we conducted
paired sample Student’s T-tests between ON and OFF
sessions. For the PDD group we conducted the Related-
Samples Wilcoxon Signed Rank Test. There was no sig-
nificant effect of dopaminergic medications in Digit
Span Backward or Forward in PD no-MCI, PD-MCI, or
PDD (Fig. 2a). However, when PD no-MCI and PD-MCI
were combined, a significant effect of the medications
was detected. In Digit Span Backward, PD participants
performed significantly better ON compared to OFF
dopaminergic medications (p = .043) (Fig. 2b).
Effect of baseline WM
Prior PD studies have shown that WM can have an
Inverted-U response to dopamine, where patients with poor
baseline (OFF dopamine) performance show improvement
after dopamine replacement and those with good baseline
performance show worsening [21, 22, 24, 33]. Therefore,
we conducted a secondary analysis to explore a possible
interaction between baseline WM and the effect of dopa-
minergic medications on Digit Span performance in our
sample. We only included PD no-MCI and PD-MCI in this
analysis due to the non-normal distribution of the PDD
group and to eliminate the possible confounding factors of
mixed pathology, elevated age, and severe impairment in
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alternate cognitive domains that could impact performance
(e.g. severe episodic memory or executive impairment that
prohibits encoding). As the cross-sectional nature of our
study prohibited evaluating premorbid WM performance,
we followed the protocol of previous studies and used the
median of the combined group Digit Span Backward OFF
to determine the cut-off score differentiating High versus
Low baseline WM in our cohort [33]. Digit Span Back-
ward ≥ 9 categorized an individual as High WM while < 9
was categorized as Low WM. Of the PD-MCI group, 16
were determined to have Low baseline WM and 6 to have
High baseline WM. Of the PD no-MCI group, 9 fell into
the Low baseline WM group and 19 in the High baseline
WM group. There were no significant differences between
motor, depression, or anxiety scores between the High and
Low groups (Table 3). We conducted separate analysis of
Digit Span Forward and Backward, each using a mixed
measures ANOVA with between-subjects factor Group
(High Baseline WM, Low Baseline WM) and within-
subjects factor Medication (ON, OFF).
Digit span forward
There was a main effect of Group (p < .001), but no
main effect of Medications. There was no interaction ef-
fect (Fig. 3a).
Digit span backward
There was a main effect of Group (p < .001), a main ef-
fect of Medication (p = .042), and no interaction effect;
however post-hoc Student’s T-tests revealed the Medica-
tion effect was only in the Low WM group (p = .002). In-
deed, the Low WM group performed significantly better
ON compared to OFF dopaminergic medications
(Fig. 3b).
Fig. 1 Performance (mean ± SE) on Digit Span Backward and Forward. The effect of Group (PDD, PD-MCI, PD no-MCI, HC) was significant in all cases. Digit
Span Forward only distinguished PDD (a and c). However, Digit Span Backward, both ON and OFF medications, successfully identified PD-MCI (b and d).
Performance represents total scores as tabulated using WAIS-IV guidelines, not digit span capacity. PD = Parkinson’s disease; PDD = PD with dementia;
PD-MCI = PD with mild cognitive impairment; PD no-MCI = PD with no cognitive impairment; HC = healthy controls. *= p< .05
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Discussion
We investigated the utility of Digit Span Backward and
Digit Span Forward as tools for identifying cognitive
impairment in PD and the effects of dopaminergic medi-
cations on Digit Span in PD. We found that Digit Span
Backward best distinguished cognitive classification
(no-MCI, MCI and dementia) in our cohort. Moreover,
exploratory analysis revealed a partial beneficial effect
of dopaminergic medications on Digit Span Backward,
with low WM individuals improving on dopamine and
high WM individuals demonstrating no benefit. Our
research provides evidence for Digit Span Backward as
a screening tool for WM impairment in PD and for its
utility in measuring baseline WM.
Digit span backwards in PD
Our findings corroborate those of Biundo et al., who re-
ported that Digit Span Backward was one of five cogni-
tive assessments that reached diagnostic and screening
validity for PD-MCI, while Digit Span Forward failed to
do so [25]. While this study only tested participants ON
dopaminergic medications, our study provides further
evidence that Digit Span Backward successfully distin-
guishes between PD no-MCI, PD-MCI, and PDD regard-
less of whether performed ON or OFF medications. By
contrast, we found Digit Span Forward was only abnor-
mal in PDD.
Moreover, we found Digit Span Backward offers greater
insight into WM impairment than the limited digit span
conducted in the MoCA. Currently, the MoCA is among
the most commonly used tools for screening PD cognitive
impairment in the clinical setting [34]. However, our find-
ings indicate the limited digit span in the MoCA is a very
weak detector of WM impairment, especially among a
population of highly educated individuals. This is in ac-
cordance with the finding that education is a strong pre-
dictor of verbal Digit Span, with higher educational
attainment leading to greater span capacity [35]. Years of
education in our cohort averaged 16 and the limited digit
span on the MoCA failed to differentiate between any of







PD no-MCI/PD-MCI 9/16 19/6
Age (years) 65.36 ± 7.26 68.72 ± 8.07 NS
Education (years) 16.16 ± 2.90 16.56 ± 2.08 NS
Duration (years) 6.17 ± 5.02 5.20 ± 3.18 NS
MDS-UPDRS III (OFF) 33.32 ± 9.22 36.68 ± 9.89 NS
MDS-UPDRS III (ON) 19.83 ± 9.22 18.75 ± 10.76 NS
BDI 11.13 ± 6.84 9.80 ± 7.99 NS
BAI 11.72 ± 10.54 11.04 ± 6.38 NS
Table depicts the mean ± standard deviation for the demographics of the
High and Low Baseline Working Memory groups
PD Parkinson’s disease, PD-MCI PD with mild cognitive impairment, PD no-MCI
PD with no cognitive impairment, MDS-UPDRS III Movement Disorders Society-
Unified Parkinson’s disease Rating Scale, motor scale, BDI Beck’s Depression
Inventory, BAI Beck’s Anxiety Inventory, NS not significant between groups
on t-test
Fig. 2 The effect of dopaminergic medication on performance on Digit Span Backward and Forward. There was no significant effect of dopaminergic
medications on Digit Span Forward (a). However, a significant effect of medications was detected in Digit Span Backward. The Combined PD group
(PD-MCI and PD no-MCI) performed significantly better ON medications than OFF medications (b). Error bars represent the Standard Error of the mean.
PD = Parkinson’s disease; PDD= PD with dementia; PD-MCI = PD with Mild Cognitive Impairment; PD no-MCI = PD with no cognitive impairment. *= p< .05
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the cognitive groups; even the vast majority of partici-
pants with dementia achieved a perfect score. Thus, we
suggest Digit Span Backward could be a relatively sim-
ple compliment to the MoCA and could be used in
clinic to screen highly educated PD patients who are
suspected of a WM deficit.
Dopaminergic effect on digit span
Prior studies in PD have reported conflicting effects of
dopaminergic medications on the verbal Digit Span,
likely due to small sample sizes. Zokaei et al previously
reported a significant dopaminergic improvement in
WM in PD patients as detected by a WM precision task,
but indicated this improvement was not detected in
Digit Span Backward or Forward [26]. On the other
hand, Cools et al found PD patients OFF medications
performed worse than healthy controls on Digit Span
Backward, but this impairment was rectified by dopa-
minergic medications [11]. Our study found a modest
degree of dopaminergic improvement similar to that of
Cools et al, but validates their finding in a much larger
cohort. In addition, our study expands upon Cools et al
by including a full neuropsychological assessment to
confirm that the dopaminergic improvement is seen in
both cognitively impaired and cognitively normal PD pa-
tients, depending on the baseline working memory.
An Inverted-U effect of dopaminergic medications has
previously been described in other WM tasks, such as
delay-response [36], and attentional set shifting [23, 33, 37].
We conducted a secondary analysis to determine a possible
interaction between baseline WM and the effect of dopa-
minergic medications specifically on the Digit Span. In
accordance with other studies exploring the Inverted-U
model [21, 24], we only detected a dopaminergic improve-
ment when groups were divided by baseline WM (Low
versus High) and not by global cognitive classification
(MCI versus no-MCI). This is likely because we our Low
and High WM groups included a distribution of both PD
no-MCI and PD-MCI individuals; 9 out of 28 PD no-MCI
had low baseline WM and 16 out of 22 PD-MCI had low
baseline WM. While it may seem counterintuitive that
patients categorized as no-MCI have low WM, this is likely
due to the threshold for determining PD no-MCI (1.5 SD
below age- and education- normative values in at least two
out of 10 tests), which allows patients to have one test more
than 1.5 SD below normative values, or have sub-threshold
poor performance on multiple tests. By contrast, PD pa-
tients who are globally categorized as cognitively impaired
do not necessarily have poor WM, as they could have
visuospatial or episodic memory impairments. Thus, our
study highlights the limitations of using global cognitive
categorization when examining a dopaminergic effect on a
specific cognitive ability and the value of identifying
Fig. 3 Dopaminergic effect is dependent on baseline WM. We determined the interaction between baseline WM and dopamine using Digit Span.
No significant effect of dopamine was detected in the Digit Span Forward in either the Low or High baseline WM groups (a). However, in Digit
Span Backward, the Low baseline WM group significantly improved ON medications. The High baseline WM Group was unaffected (b). Error bars
represent the Standard Error of the mean. PD = Parkinson’s disease; PD-MCI = PD with mild cognitive impairment; PD no-MCI = PD with no cognitive
impairment; WM=working memory. * = p < .05
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validated tests for PD patients in individual cognitive
domains. Due to the cross-sectional nature of our study,
baseline WM was determined using performance on Digit
Span Backward OFF medications. Although pre-morbid
WM would have been a preferable baseline, using perform-
ance when OFF medications enabled us to isolate the effect
of dopamine from that of the primary disease.
The Inverted-U hypothesis predicts that the effect of
dopamine depends upon baseline WM and the nature of
the cognitive task being performed. Specifically, tasks
that require high levels of stabilization should benefit
from high levels of dopamine in the prefrontal cortex
relative to the striatum [10, 22, 24, 38]. Therefore, poor
baseline WM suggests an imbalance of dopamine be-
tween the prefrontal cortex and striatum, and high base-
line WM indicates an optimized balance [22, 24, 38]. In
addition, this hypothesis suggests that low WM individuals
should benefit from dopaminergic medications on straight-
forward WM tasks that require cognitive stabilization, such
as Digit Span, while high WM individuals should be detri-
mentally affected. Our study was not optimized to fully
explore this relationship because we could only divide our
cohort into two groups (high and low WM) and a true
Inverted-U effect would ideally show those who improve,
those who do not change, and those who are detrimentally
affected; however some of our findings can be explained
within this framework. For instance, dopaminergic medica-
tions might have benefited the low WM individuals by
shifting the dopamine balance between the prefrontal cor-
tex and the striatum to a more optimal level [24, 38]. Our
high WM individuals were unaffected by dopamine, pos-
sibly because dopaminergic medications did not alter the
balance (i.e. they were already optimized). An alternative
explanation is that, unlike other WM tasks, Digit Span
Backward does not follow an Inverted-U dopaminergic
response due to the simplicity of the task. Further studies
optimized to explore this question, ideally with more diffi-
cult WM tasks, could clarify this distinction.
Practical applications for the digit span backward
As described above, we established Digit Span Backward
as an accurate predictor of baseline WM. In concordance
with Lewis et al, which revealed effects of dopaminergic
medications on the manipulation but not maintenance
stage of WM, the Inverted-U was only detected in Digit
Span Backward and not Digit Span Forward [15]. Our
findings indicate that Digit Span Backward can be used to
differentiate between low and high WM individuals in
clinical and research settings.
An important consequence of the detected dopamin-
ergic effect on the Digit Span Backward is that the task
is a more sensitive determinate of baseline WM when it
is conducted OFF medications. As the medications im-
prove performance in the Low WM group but do not
affect the High WM group, they effectively blur the line
between high and low WM individuals such that in the
ON medications state some low WM individuals could
inadvertently be categorized as high WM. As such, we
recommend the Digit Span Backward be conducted OFF
medications if possible when being used to primarily
identify low baseline WM individuals.
Methodology and limitations
Our study has several limitations. It should be noted
that our PDD group was significantly older than our PD
no-MCI and HC groups. The age difference, in addition
to possible mixed-pathology, confounds our ability to
determine whether the significantly impaired perform-
ance of the PDD group on Digit Span Forward was a
direct effect of PDD or influenced by the effect of age.
We were also unable to determine baseline WM for the
PD patients prior to onset of disease. This limits our
ability to determine whether impairments represent an
individual’s pre-morbid cognitive ability or are a result of
PD. However, our findings remain significant for clinical
purposes as they offer clinicians a tool to predict the
effects of dopaminergic medications on WM. Moreover,
it is difficult to generalize our findings to all PD patients
since our cohort was not necessarily representative. Not-
ably, our PD no-MCI and PD-MCI groups did not
perform significantly differently than HC on any task,
regardless of medication status. This could be due to
motivation of PD patients to perform well [39–41], or
because 6 out of 22 PD MCI participants had high base-
line WM. Generalizability of our findings is also a con-
cern; PD patients were primarily recruited from an
academic tertiary care center, resulting in a highly edu-
cated cohort.
Finally, we recognize that Digit Span Backward does
not test all aspects of WM and cognition. Notably, Cools
et al previously reported that improvement in WM on
Digit Span Backward was counterbalanced by increased
distractibility in PD patients, indicating dopaminergic
medications were beneficial to some aspects of cognition
and detrimental to others [11]. Further studies should
investigate the longitudinal validity of Digit Span Backward
and the effects of dopaminergic medications on other
cognitive functions, such as attentional control. Moreover,
neuroimaging studies can lead to a deeper understanding
of whether the dopaminergic effect we detected represents
a stabilization of the balance between the prefrontal cortex
and the striatum [24].
Conclusions
Our research supports the use of Digit Span Backward to
screen for mild cognitive impairment, particularly among
highly educated PD patients, and to detect baseline WM.
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It also suggests a partial beneficial effect of dopaminergic
medications on verbal Digit Span Backward in PD.
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